The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

Huijun Zhao(Ministry of Education of the People's Republic of China), Man Zhang(Capital Medical University), Juan Ma(Shandong University of Technology), Ting Lei(Sichuan University), Wanru Ma(Peking University Cancer Hospital)
Investigational New Drugs
October 29, 2018
Cited by 19


Related Papers